Product Information
Registration Status: ActiveZANTAC SYRUP 150mg/10ml is approved to be sold in Singapore with effective from 1989-04-19. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN02543P.
This product contains Ranitidine 150mg/10ml in the form of SYRUP. It is approved for ORAL use.
This product is manufactured by ASPEN BAD OLDESLOE GmbH in GERMANY, andGLAXO WELLCOME OPERATIONS in UNITED KINGDOM.
It is a has been granted the exemption for supply without a presciption if it met certain criteria.
Description
A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. [PubChem]
Indication
Used in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).
Mechanism of Action
The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.
Pharmacokinetics
- Absorption
- Approximately 50% bioavailability orally.
- Distribution
- * 1.4 L/kg * 1.76 L/kg [clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min)]
- Metabolism
- Hepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively.
- Elimination
Clearance
* 29 mL/min [clinically significant renal function impairment] * 3 mL/min/Kg [neonatal patients]
Toxicity
LD50=77mg/kg (orally in mice). Symptoms of overdose include muscular tremors, vomiting, and rapid respiration.
Active Ingredient/Synonyms
RAN | Ranitidina | Ranitidinum | Ranitidine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.